Dynavax Technologies (DVAX) Expected to Announce Earnings on Tuesday

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $70.01 million for the quarter.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Trading Down 1.3 %

Shares of DVAX stock traded down $0.15 during mid-day trading on Friday, reaching $11.33. 1,750,419 shares of the stock traded hands, compared to its average volume of 2,203,668. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 62.94 and a beta of 1.26. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock's fifty day simple moving average is $12.59 and its two-hundred day simple moving average is $12.59. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.63.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.